Abstract P2-04-10: ARL3 Promotes Hormone Receptor Positive Breast Cancer Progression and Tamoxifen Resistance through ERα Stablization

Li Han, Yang Liu, Zehao Cai, Dan Shu, Peng Yang, Shuo Li, Shengchun LiuClinical 2025 · DOI

Abstract

Abstract Background: Hormone Receptor Positive (HR+) breast cancer is predominantly managed with endocrine therapies that target the Estrogen Receptor Alpha (ERα), a key mediator of estrogen's role in promoting tumor growth. However, the emergence of endocrine resistance poses a significant clinical challenge, limiting the efficacy of these treatments and impeding optimal patient outcomes. Understanding the mechanisms behind ERα's importance and the development of resistance is crucial for advancing therapeutic strategies against HR+ breast cancer. Methods: In our study, we utilized the GEO database to identify ADP-Ribosylation Factor-Like GTPase 3 (ARL3) as a gene associated with tamoxifen resistance in HR+ breast cancer. We constructed cell lines with ARL3 knockout and overexpression to assess the impact of ARL3 on cell proliferation, migration, and tamoxifen sensitivity. RNA sequencing (RNA-seq) and liquid chromatography-mass spectrometry (LC/MS) were employed to demonstrate the influence of ARL3 knockout on downstream ERα pathways. Furthermore, co-immunoprecipitation (CO-IP), immunofluorescence and Western blot (WB) assays confirmed the role of ARL3 in the ubiquitination and degradation pathway of ERα. Results: In our analysis of TCGA breast cancer subtypes, we also observed that ARL3 is highly expressed in luminal breast cancer. Additionally, our collection of breast cancer tissue mRNA and immunohistochemistry data revealed that ARL3 expression is elevated in HR+ breast cancer, indicating a correlation with estrogen receptors. We found that ARL3 promotes the proliferation and migration of HR+ breast cancer. Furthermore, overexpression of ARL3 was associated with reduced sensitivity to tamoxifen, and in vivo tumorigenesis in nude mice showed that tumor volume and weight were significantly decreased compared to the control group. To investigate the underlying mechanisms, RNA-seq analysis of ARL3 knockout and control groups revealed a pronounced inhibition of the MYC pathway. Western blot (WB) validation confirmed that ARL3 knockout suppresses the expression of downstream pathways of ERα. Our data suggest that the association between ARL3 and ERα primarily occurs in the cytoplasm, mainly binding to the ligand-binding domain (LBD) of ERα, which is consistent with ARL3 not being recruited to the promoters occupied by ERα. We also discovered that the ARL3/ERα cascade promotes mitochondrial autophagy to enhance mitochondrial oxidative phosphorylation. In summary, our study establishes a non-genomic mechanism whereby ARL3 controls the transcription of estrogen-dependent genes associated with breast cancer cell proliferation by stabilizing ERα levels. Conclusion: In our study, we posit that ADP-ribosylation factor-like GTPase 3 (ARL3) exerts a pivotal influence on the proliferative capacity, metastatic potential, and responsiveness to endocrine therapies in hormone receptor-positive (HR+) breast cancer. ARL3 modulates the stability of estrogen receptor alpha (ERα), thereby regulating the activation of downstream signaling cascades and the mitochondrial functionality within neoplastic cells. Our findings suggest that ARL3 represents a promising therapeutic target for HR+ breast cancer. We envision that in-depth investigation into the molecular underpinnings of ARL3's role could pave the way for the development of innovative pharmacological agents capable of overcoming endocrine resistance in patients, ultimately enhancing their clinical outcomes and survival rates. Citation Format: Han Li, Yang Liu, Zehao Cai, Dan Shu, Yang Peng, Kang Li, Shengchun Liu. ARL3 Promotes Hormone Receptor Positive Breast Cancer Progression and Tamoxifen Resistance through ERα Stablization [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P2-04-10.
BibTeX
@inproceedings{han2025abstract,
  author = {Li Han and Yang Liu and Zehao Cai and Dan Shu and Peng Yang and Shuo Li and Shengchun Liu},
  title = {{Abstract P2-04-10: ARL3 Promotes Hormone Receptor Positive Breast Cancer Progression and Tamoxifen Resistance through ERα Stablization}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1158/1557-3265.sabcs24-p2-04-10},
}

Loading related content...

Figure